Total Funding
14
64
Total FundingVenture - Series Unknown raised
Growth Score
-27 pts
Heat Score
14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
81165
Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.
James Liu: Director of System Architecture
Ming Hsieh: President & Chief Executive OfficerPast Role: Cogent Systems, Co-founder, CEO, President, and Chairman
About the Company
Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). Apart from traditional single gene tests, Fulgent Therapeutics has been investing heavily in the future. Using Next Generation Sequencing (NGS) technology we are developing a new series of panel based tests for our clients.
